Market Entry Strategy

UroPharma’s initial strategy is to bring dtb therapeutics to people with MS in the US, UK and Europe

strategy-and-tactics-pro-.png

UroPharma’s own market research indicates that many people with Multiple Sclerosis MS (who are already self-catheterizing) will choose dtb therapy throughout their lives because of its effectiveness and minimal side effect profile, which translates to a potential recurring revenue stream for UroPharma.